Biodexa Pharmaceuticals (BDRX) Current Assets (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Current Assets of $16.6 million for Q4 2025, up 37.98% sequentially from $12.0 million in Q2 2025, and up 46.37% YoY from $11.3 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Current Assets (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Current Assets for 13 years, with the latest figure at $16.6 million in Q4 2025.
- Quarterly Current Assets rose 46.37% year-over-year to $16.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.6 million (up 46.37% YoY) and the FY2025 annual result came in at $16.4 million, up 45.09% from the prior year.
- Current Assets climbed to $16.6 million in Q4 2025 per BDRX's latest filing, from $12.0 million in the prior quarter.
- Over five years, Current Assets peaked at $16.6 million in Q4 2025 and troughed at $5.5 million in Q4 2022.
- A 5-year average of $10.9 million and a median of $10.4 million in 2021 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2023: Current Assets sank 65.32% in 2022, then jumped 58.68% in 2023.
- Over 5 years, Current Assets stood at $15.9 million in 2021, then tumbled by 65.32% to $5.5 million in 2022, then jumped by 58.68% to $8.7 million in 2023, then increased by 29.6% to $11.3 million in 2024, then jumped by 46.37% to $16.6 million in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $16.6 million, $12.0 million, and $11.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | 16.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.55 Mn |
| Jun 30, 2025 | 12.00 Mn |
| Dec 31, 2024 | 11.31 Mn |
| Jun 30, 2024 | 9.50 Mn |
| Dec 31, 2023 | 8.73 Mn |
| Jun 30, 2023 | 9.09 Mn |
| Dec 31, 2022 | 5.50 Mn |
| Jun 30, 2022 | 10.94 Mn |
| Dec 31, 2021 | 15.85 Mn |
| Jun 30, 2021 | 9.82 Mn |
| Dec 31, 2020 | 12.25 Mn |
| Jun 30, 2020 | 12.75 Mn |
| Dec 31, 2019 | 17.66 Mn |
| Jun 30, 2019 | 18.43 Mn |
| Dec 31, 2018 | 7.23 Mn |
| Jun 30, 2018 | 27.91 Mn |
| Dec 31, 2017 | 24.67 Mn |
| Jun 30, 2017 | 14.96 Mn |
| Dec 31, 2016 | 27.73 Mn |
| Jun 30, 2016 | 16.14 Mn |